Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT.

Gary-Bobo M, Hocine O, Brevet D, Maynadier M, Raehm L, Richeter S, Charasson V, Loock B, Morère A, Maillard P, Garcia M, Durand JO.

Int J Pharm. 2012 Feb 28;423(2):509-15. doi: 10.1016/j.ijpharm.2011.11.045. Epub 2011 Dec 8.

PMID:
22178618
2.

Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug sensitivity using the NCI-60 panel as a model.

Charasson V, Hillaire-Buys D, Solassol I, Laurand-Quancard A, Pinguet F, Le Morvan V, Robert J.

Eur J Cancer. 2009 Sep;45(13):2391-401. doi: 10.1016/j.ejca.2009.05.013. Epub 2009 Jun 6.

PMID:
19501504
3.

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.

Rouits E, Charasson V, Pétain A, Boisdron-Celle M, Delord JP, Fonck M, Laurand A, Poirier AL, Morel A, Chatelut E, Robert J, Gamelin E.

Br J Cancer. 2008 Oct 21;99(8):1239-45. doi: 10.1038/sj.bjc.6604673. Epub 2008 Sep 16.

4.

Comparison of carbamazepine and oxcarbazepine effects on aminothiol levels.

Badiou S, Breton H, Peyriere H, Charasson V, Crespel A, Gelisse P, Cristol JP, Hillaire-Buys D.

Eur J Clin Pharmacol. 2008 Jan;64(1):83-7. Epub 2007 Oct 31.

PMID:
17972070
5.

Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene.

Bellott R, Le Morvan V, Charasson V, Laurand A, Colotte M, Zanger UM, Klein K, Smith D, Bonnet J, Robert J.

Cancer Chemother Pharmacol. 2008 Mar;61(3):481-8. Epub 2007 May 5.

PMID:
17483951
6.

Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38.

Charasson V, Bellott R, Meynard D, Longy M, Gorry P, Robert J.

Clin Pharmacol Ther. 2004 Dec;76(6):528-35.

PMID:
15592324
7.

Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study.

Pavillard V, Charasson V, Laroche-Clary A, Soubeyran I, Robert J.

Anticancer Res. 2004 Mar-Apr;24(2B):579-85.

8.

Determination of drug interactions occurring with the metabolic pathways of irinotecan.

Charasson V, Haaz MC, Robert J.

Drug Metab Dispos. 2002 Jun;30(6):731-3.

PMID:
12019202
9.

Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.

Pavillard V, Agostini C, Richard S, Charasson V, Montaudon D, Robert J.

Cancer Chemother Pharmacol. 2002 Apr;49(4):329-35. Epub 2002 Jan 30.

PMID:
11914913
10.

In vitro study of the percutaneous absorption of four aromatic amines using hairless rat skin.

Levillain F, Charasson V, el Marbouh L, Poëy J, Houin G.

Arzneimittelforschung. 1998 Sep;48(9):948-51.

PMID:
9793624

Supplemental Content

Loading ...
Support Center